- Home
- AVBP vs OPT Comparison
AVBP vs OPT Comparison
Compare AVBP & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- OPT
- Stock Information
- Founded
- AVBP 2021
- OPT 1984
- Country
- AVBP United States
- OPT Australia
- Employees
- AVBP N/A
- OPT N/A
- Industry
- AVBP
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVBP
- OPT Health Care
- Exchange
- AVBP NYSE
- OPT Nasdaq
- Market Cap
- AVBP 925.7M
- OPT 767.9M
- IPO Year
- AVBP 2024
- OPT 2020
- Fundamental
- Price
- AVBP $27.52
- OPT $3.76
- Analyst Decision
- AVBP Strong Buy
- OPT Strong Buy
- Analyst Count
- AVBP 5
- OPT 1
- Target Price
- AVBP $36.80
- OPT $12.00
- AVG Volume (30 Days)
- AVBP 152.3K
- OPT 9.7K
- Earning Date
- AVBP 02-02-2025
- OPT 02-26-2025
- Dividend Yield
- AVBP N/A
- OPT N/A
- EPS Growth
- AVBP N/A
- OPT N/A
- EPS
- AVBP N/A
- OPT N/A
- Revenue
- AVBP N/A
- OPT $261,859.00
- Revenue This Year
- AVBP N/A
- OPT N/A
- Revenue Next Year
- AVBP N/A
- OPT $46,864.64
- P/E Ratio
- AVBP N/A
- OPT N/A
- Revenue Growth
- AVBP N/A
- OPT N/A
- 52 Week Low
- AVBP $14.35
- OPT $1.79
- 52 Week High
- AVBP $36.37
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- AVBP 50.18
- OPT 54.66
- Support Level
- AVBP $26.36
- OPT $3.53
- Resistance Level
- AVBP $27.67
- OPT $4.00
- Average True Range (ATR)
- AVBP 1.27
- OPT 0.20
- MACD
- AVBP 0.18
- OPT 0.06
- Stochastic Oscillator
- AVBP 71.82
- OPT 72.00
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.